ArticleNews reportPHN-05102026-11-01 17:09 CT

China Has 21 of Asia-Pacific's 30 Obesity Drug Candidates, South Korea Follows With Six

Source · 아시아경제

TLDR

According to BioPharma APAC figures cited by 아시아경제, China accounts for 21 of 30 Asia-Pacific obesity drug candidates at the clinical-trial stage or beyond, followed by South Korea with six. The article reports approximately $1.04 billion in disclosed upfront licensing payments, excluding a separate €62 million deal.

01—Key points

01The article reports three approvals among the 30 candidates and three Chinese GLP-1/GIP dual agonists awaiting approval.
02Rights to 13 candidates are held by licensees, European partners outside the region, or global license holders.
03KoreaBIO’s Bioeconomy Research Center identifies muscle preservation as an emerging development priority and cautions that clinical data are difficult to compare directly.

Why it matters Editorial

The report highlights Asia-developed intellectual property and international licensing activity in next-generation obesity treatments, including GLP-1/GIP dual agonists.

Read the original at 아시아경제↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.